Mainz Biomed N.V. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MYNZ Nasdaq 2836 mainzbiomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mainz Biomed N.V.

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - Mar 13th, 2025 12:01 pm
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - Mar 3rd, 2025 1:01 pm
Mainz Biomed Expands into Switzerland with labor team w - Feb 20th, 2025 1:01 pm
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month - Feb 11th, 2025 1:01 pm
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - Jan 27th, 2025 1:01 pm
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Jan 21st, 2025 1:01 pm
Mainz Biomed partners with Quest for colorectal cancer screening test - Dec 20th, 2024 3:31 pm
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Dec 19th, 2024 1:01 pm
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - Dec 16th, 2024 10:00 pm
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - Dec 13th, 2024 1:00 am
Mainz Biomed Announces Stock Split - Nov 29th, 2024 1:45 pm
The Oncology Bet Is Already Paying Off For Pfizer - Nov 14th, 2024 12:23 am
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Nov 12th, 2024 2:00 pm
Mainz Biomed restructured operations, implemented cost reductions - Oct 22nd, 2024 12:10 pm
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - Oct 21st, 2024 12:01 pm
Mainz Biomed Secures Additional $1.5M Funding - Oct 10th, 2024 9:37 pm
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version - Oct 8th, 2024 12:01 pm
The Covid Era Tech Promises To Reinvent Cancer Treatment - Oct 1st, 2024 6:11 pm
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - Oct 1st, 2024 12:01 pm
Pfizer Advances On Its Cancer Journey - Sep 20th, 2024 2:48 pm